ImegenImegen

  • Twitter
  • Facebook
  • YouTube
  • LinkedIn
  • en 
  • es 
Cáncer hereditario
Customer area
  • Products and Services
    • Prenatal stage
      • Non-Invasive Prenatal Test
      • Prenatal diagnosis
      • Prenatal diagnosis of a rare disease
    • Pediatric stage
      • Neuropaediatric disorders
      • Genetic syndromes
      • Diagnosis of rare diseases
    • Adult stage
      • Diagnosis of rare diseases
      • Reproductive screening
      • Cancer
    • IMEXOME
    • Kits for analysis
  • Hospitals and Specialists
    • Kits for analysis
    • Techniques available
  • Patients and Families
    • Genetic guide
    • Non-Invasive Prenatal Test
  • R&D
    • Partner profile
    • R&D projects
  • About us
    • About us
    • Team
    • Excellent quality
HomeProducts and ServicesAdult stage

Adult stage

The adult stage is the longest period of our lives, lasting for around 60-70 years, during which time we can be diagnosed with a genetic disease and also be able prevent it from being passed on to our children. Prevention, an analysis of the family history and an ability to take informed and well thought-out decisions as regards opting for a genetic diagnosis or when considering extending the family or living with greater peace of mind are essential during this stage.

Find your genetic test
Advanced search

Products

Exome

Clinic

Kits

by specialty

NextGENe

based on NGS

The main advantages

The main advantages of a genetic analysis at this stage include:

An accurate diagnosis
An early diagnosis
Genetic counselling
Clear information
Causes

An accurate diagnosis, thus reducing uncertainty.

An early diagnosis that allows therapy or treatment to be proposed as soon as possible.

Receiving genetic counselling concerning the family risks, thus allowing family planning.

An ability to provide clear information to allow the person concerned to come to terms with their new situation.

Identification of the molecular causes of the disease, which is essential to propose other genetic analyses of a preventive nature.

 

Services

Reproductive screening

Recessive diseases are those that only arise when an abnormal gene has been passed on by two healthy parents…

Diagnosis of rare diseases

Rare diseases have a low incidence in the population of less than 1 in every 200 inhabitants…

Cáncer

Cancer is a multifactorial disease in which both genetic and environmental factors play a role…

Techniques available

IMEGEN use the most accurate and up-to-date genetic analysis techniques. The optimal diagnostic efficacy is obtained by selecting the most appropriate technique for each clinical case.

More info

Request Information

Please fill out the form below to request any information about our products and services, or call us at  +34 963 212 340.

Name
Company
Phone
E-mail
Message

Acept legal conditions

I understand and accept this Privacy Policy by checking this box

I consent the use of my personal data to receive publicity of your entity YesNo

Customer area

I forgot my password New user Close

Instituto de Medicina Genómica, S.L.

Founded in 2009 by a team of scientists with more than 20 years’ business experience, it has since grown to become the leader in the genetics and genomics sector.

Meet Imegen

  • Products and Services
    • Prenatal stage
      • Non-Invasive Prenatal Test
      • Prenatal diagnosis
      • Prenatal diagnosis of a rare disease
    • Pediatric stage
      • Neuropaediatric disorders
      • Genetic syndromes
      • Diagnosis of rare diseases
    • Adult stage
      • Diagnosis of rare diseases
      • Reproductive screening
      • Cancer
    • IMEXOME
    • Kits for analysis
  • Hospitals and Specialists
    • Kits for analysis
    • Techniques available
  • Patients and Families
    • Genetic guide
    • Non-Invasive Prenatal Test
  • R&D
    • Partner profile
    • R&D projects
  • About us
    • About us
    • Team
    • Excellent quality

Contact

c/ Agustín Escardino 9, Parc Científic de la Universitat de València - 46980 Paterna

info@imegen.es
Tel: +34 963 212 340

Empresa cofinanciada por:
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy